Free Trial

Uniphar (LON:UPR) Hits New 1-Year High - What's Next?

Uniphar logo with Medical background

Key Points

  • Uniphar plc (LON:UPR) achieved a new 52-week high at GBX 348 ($4.71) during trading, with an increase from a previous close of GBX 339 ($4.59).
  • Analysts have recently set new price targets, with Shore Capital maintaining a "buy" rating, while Deutsche Bank set a price objective of GBX 375 ($5.07) and reaffirmed a "hold" rating.
  • The company has a market capitalization of £1.05 billion and operates across three divisions servicing over 200 pharmaceutical and medical technology manufacturers.
  • Looking to export and analyze Uniphar data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Uniphar plc (LON:UPR - Get Free Report) hit a new 52-week high on Friday . The stock traded as high as GBX 348 ($4.70) and last traded at GBX 348 ($4.70), with a volume of 8648 shares changing hands. The stock had previously closed at GBX 339 ($4.58).

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Shore Capital reaffirmed a "buy" rating on shares of Uniphar in a report on Thursday, May 29th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and issued a GBX 375 price objective on shares of Uniphar in a report on Wednesday, July 30th. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of GBX 375.

Check Out Our Latest Stock Report on UPR

Uniphar Price Performance

The company has a debt-to-equity ratio of 119.48, a quick ratio of 0.60 and a current ratio of 0.90. The company has a market cap of £1.08 billion, a price-to-earnings ratio of 24.11 and a beta of 0.75. The business has a fifty day moving average price of GBX 327.62 and a 200 day moving average price of GBX 270.71.

Uniphar Company Profile

(Get Free Report)

Headquartered in Dublin, Ireland Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions – Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK and the Benelux.

See Also

Should You Invest $1,000 in Uniphar Right Now?

Before you consider Uniphar, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Uniphar wasn't on the list.

While Uniphar currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Follow the Money: 5 Stocks Institutions Are Buying NOW
Palantir’s Soaring Valuation—Justified or Overhyped?
3 Stocks With Explosive Upside

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines